Antidiabetic and Antidyslipidemic Effects of Artemisia mesatlantica, an Endemic Plant from Morocco.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2023-01-01 DOI:10.2174/1871529X23666230803113616

Adil Qabouche, Ayoub Amssayef, Ismail Bouadid, Nadia Lahrach, Ahmed El-Haidani, Mohamed Eddouks

{"title":"Antidiabetic and Antidyslipidemic Effects of Artemisia mesatlantica, an Endemic Plant from Morocco.","authors":"Adil Qabouche, Ayoub Amssayef, Ismail Bouadid, Nadia Lahrach, Ahmed El-Haidani, Mohamed Eddouks","doi":"10.2174/1871529X23666230803113616","DOIUrl":null,"url":null,"abstract":"Aims: The study aimed to assess the antihyperglycemic and antidyslipidemic activities of Artemisia mesatlantica.Background: Artemisia mesatlantica is an endemic plant of Morocco used in traditional medicine as an alternative treatment for diabetes.Objective: The study was designed to examine the antihyperglycemic and antidyslipidemicability of aqueous extract of Artemisia mesatlantica (AMAE) in experimental animal models.Methods: The effect of the single and repeated oral administration (7 days of treatment) of AMAE (60 mg/kg) on blood glucose and lipid profile were assessed in normal and streptozotocin-induced diabetic rats. Furthermore, to confirm the antidyslipidemic effect of Artemisia mesatlantica, a model of hyperlipidemia induced by tyloxapol (Triton WR-1339) in rats was used.Results: The AMAE (60 mg/kg) was able to significantly reduce glycaemia, improve lipid profile and increase hepatic glycogen content in STZ-induced diabetic rats. In addition, pretreatment of rats for 7 consecutive days with an aqueous extract of Artemisia mesatlantica (600 mg/kg) prior to tyloxapol injection prevented increases in plasma levels of total cholesterol, triglycerides and LDL-c.Conclusion: From these observed results, it can be deduced that Artemisia mesatlantica possesses remarkable antidiabetic and antihyperlipidemic properties.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":" ","pages":"50-63"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X23666230803113616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The study aimed to assess the antihyperglycemic and antidyslipidemic activities of Artemisia mesatlantica.

Background: Artemisia mesatlantica is an endemic plant of Morocco used in traditional medicine as an alternative treatment for diabetes.

Objective: The study was designed to examine the antihyperglycemic and antidyslipidemicability of aqueous extract of Artemisia mesatlantica (AMAE) in experimental animal models.

Methods: The effect of the single and repeated oral administration (7 days of treatment) of AMAE (60 mg/kg) on blood glucose and lipid profile were assessed in normal and streptozotocin-induced diabetic rats. Furthermore, to confirm the antidyslipidemic effect of Artemisia mesatlantica, a model of hyperlipidemia induced by tyloxapol (Triton WR-1339) in rats was used.

Results: The AMAE (60 mg/kg) was able to significantly reduce glycaemia, improve lipid profile and increase hepatic glycogen content in STZ-induced diabetic rats. In addition, pretreatment of rats for 7 consecutive days with an aqueous extract of Artemisia mesatlantica (600 mg/kg) prior to tyloxapol injection prevented increases in plasma levels of total cholesterol, triglycerides and LDL-c.

Conclusion: From these observed results, it can be deduced that Artemisia mesatlantica possesses remarkable antidiabetic and antihyperlipidemic properties.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

摩洛哥特有植物马先蒿的抗糖尿病和血脂异常作用。

目的：评价高原蒿的降血糖、降血脂作用。背景：大西洋蒿是摩洛哥的特有植物，在传统医学中被用作糖尿病的替代治疗方法。目的：在实验动物模型中考察高原蒿水提取物（AMAE）的抗高血糖和降脂作用。方法：在正常和链脲佐菌素诱导的糖尿病大鼠中，评估单次和多次口服（治疗7天）AMAE（60mg/kg）对血糖和血脂的影响。此外，为了证实美沙蒿的抗血脂作用，使用了由泰洛沙姆（Triton WR-1339）诱导的大鼠高脂血症模型。结果：AMAE（60mg/kg）能显著降低STZ诱导的糖尿病大鼠的血糖，改善脂质状况，增加肝糖原含量。此外，在注射替洛沙醇之前，大鼠连续7天用美沙蒿水提取物（600 mg/kg）预处理，可防止血浆总胆固醇、甘油三酯和低密度脂蛋白水平的升高。结论：从这些观察结果可以推断，美沙蒿具有显著的抗糖尿病和抗高脂血症特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.